Simulation and prediction of the drug‐drug interaction potential of naloxegol by physiologically based pharmacokinetic modeling
Naloxegol, a peripherally acting μ‐opioid receptor antagonist for the treatment of opioid‐
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
D Zhou, K Bui, M Sostek… - CPT: pharmacometrics …, 2016 - pubmed.ncbi.nlm.nih.gov
Naloxegol, a peripherally acting μ-opioid receptor antagonist for the treatment of opioid-
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
D Zhou, K Bui, M Sostek, N Al‐Huniti - CPT: Pharmacometrics & Systems …, 2016 - cir.nii.ac.jp
抄録< jats: p> Naloxegol, a peripherally acting μ‐opioid receptor antagonist for the treatment
of opioid‐induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
of opioid‐induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
[PDF][PDF] Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
D Zhou, K Bui, M Sostek, N Al-Huniti - researchgate.net
METHODS Clinical studies Clinical DDI study results of orally administered naloxegol 25 mg
and various CYP3A and P-gp inhibitors (ketoconazole, diltiazem, and quinidine) and an …
and various CYP3A and P-gp inhibitors (ketoconazole, diltiazem, and quinidine) and an …
[HTML][HTML] Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
D Zhou, K Bui, M Sostek, N Al‐Huniti - CPT: Pharmacometrics & …, 2016 - ncbi.nlm.nih.gov
Naloxegol, a peripherally acting μ‐opioid receptor antagonist for the treatment of opioid‐
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
[PDF][PDF] Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
D Zhou, K Bui, M Sostek, N Al-Huniti - cyberleninka.org
METHODS Clinical studies Clinical DDI study results of orally administered naloxegol 25 mg
and various CYP3A and P-gp inhibitors (ketoconazole, diltiazem, and quinidine) and an …
and various CYP3A and P-gp inhibitors (ketoconazole, diltiazem, and quinidine) and an …
Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
D Zhou, K Bui, M Sostek… - CPT: Pharmacometrics & …, 2016 - search.proquest.com
Naloxegol, a peripherally acting μ‐opioid receptor antagonist for the treatment of opioid‐
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling.
D Zhou, K Bui, M Sostek, N Al-Huniti - CPT: Pharmacometrics & …, 2016 - europepmc.org
Naloxegol, a peripherally acting μ‐opioid receptor antagonist for the treatment of opioid‐
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling.
D Zhou, K Bui, M Sostek… - CPT: Pharmacometrics & …, 2016 - search.ebscohost.com
Naloxegol, a peripherally acting μ-opioid receptor antagonist for the treatment of opioid-
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling.
D Zhou, K Bui, M Sostek, N Al-Huniti - CPT: Pharmacometrics & …, 2016 - europepmc.org
Naloxegol, a peripherally acting μ‐opioid receptor antagonist for the treatment of opioid‐
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …
induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P …